Abstract 75P
Background
The sodium-dependent phosphate transporter NaPi2b is a promising target for the treatment of malignant tumors due to its increased expression in several oncological diseases. NaPi2b is a target for therapeutic monoclonal antibodies directed against the MX35 epitope within the large extracellular domain (ECD) of the NaPi2b. We assume that this epitope has tumor-specific conformation that is formed due to the creation of disulfide bonds between four cysteine residues at positions 303, 322, 328 and 350. The proline residue at position 325 lies between cysteines 322 and 328 in the region of the MX35 epitope of NaPi2b. We assume that proline at this position due to its formation of a bend in the structure of the peptide participates in the formation of a disulfide bond between cysteines at positions 322 and 328 that is critical in the recognition of the MX35 epitope by antibodies. To verify this, the mutant form with the proline replacement should be evaluated using antibodies against the MX35 epitope in Western blot and microscopy analysis. The aim of this work was to create a genetic construct encoding the mutant form of the NaPi2b transporter with the replacement of proline with alanine at position 325.
Methods
To carry out site-directed mutagenesis, we selected primers with the replacement of triplets encoding proline at position 325 with a triplet encoding alanine in the SLC34A2 (encoding transporter NaPi2b) gene. The resulting PCR product was transformed into E.coli cells of the XL1-Blue strain and plasmid DNA was isolated. To confirm the mutation, samples were sequenced using the Sanger method.
Results
As a result of our work, we created a genetic construct with the replacement of proline with alanine at position 325 of the NaPi2b transporter, which will be further test in Western blot and microscopy analysis by monoclonal antibodies.
Conclusions
The obtained results supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030) are important for further study of the mechanism of recognition of the MX35 NaPi2b epitope by monoclonal antibodies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Research Laboratory \"Biomarker\", Institute of Fundamental Medicine and Biology, Kazan Federal University.
Funding
This work has been supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract